Most Common Side Effects of Ebglyss
Ebglyss (lebrikizumab-lbkz) is an IL-13 inhibitor injection approved for moderate-to-severe atopic dermatitis in adults and children 12 years and older whose condition is not adequately controlled with topical therapies. The most common side effects, occurring in at least 1% of patients in clinical trials, are eye and eyelid inflammation, including conjunctivitis, conjunctival redness, dry eye, blurred vision, and eye irritation.[1][2]
How Often Do They Happen?
In phase 3 trials (ADvocate1, ADvocate2, ADjoin), conjunctivitis affected 7-19% of Ebglyss patients versus 2-5% on placebo. Herpes infections (cold sores or shingles) occurred in 2-3% versus less than 1% on placebo. Injection site reactions hit 3% versus 1% on placebo.[1][3]
Why Eye Issues Specifically?
Ebglyss targets interleukin-13, a cytokine driving skin inflammation in eczema, but this pathway also influences eye tissues, raising conjunctivitis risk—a class effect seen with other biologics like dupilumab (Dupixent).2
What Should Patients Watch For?
Mild cases often resolve without stopping treatment, but severe eye symptoms may need ophthalmologist evaluation. Report herpes flares or injection pain promptly. No increased risk of serious infections overall.[1][2]
How Does It Compare to Dupixent?
Ebglyss has similar eye side effects to Dupixent (conjunctivitis in 10-20%), but lower rates of injection site reactions (3% vs. 10-15%). Both improve eczema scores, but Ebglyss dosing is every 2 weeks after loading doses.3
[1]: https://www.ebglyss.com/side-effects
[2]: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761349s000lbl.pdf (FDA Label)
[3]: https://www.nejm.org/doi/full/10.1056/NEJMoa2206714 (ADvocate1/2 Trials)